CN Mobile Logo

Search form


Prostate Cancer

Active Surveillance for Prostate Cancer: How to Do It Right

In this review of active surveillance for favorable-risk prostate cancer, we will discuss the rationality of this approach, the biological evidence for employing active surveillance in Gleason pattern 3 and 4 prostate cancer, patient selection for active surveillance, clinical trial data on active surveillance, and the role of prostate cancer biomarkers and imaging studies for clinical decision making in patients with low-risk disease.

Prostate Cancer

Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease.

Immediate treatment with androgen-deprivation therapy for men with asymptomatic non-curable prostate cancer did not have major effects on quality of life compared with delayed use, according to a phase III trial.

Men with non-metastatic prostate cancer who receive androgen deprivation therapy risk loss of bone mineral density and fractures, but both bisphosphonates and denosumab can improve their bone health.

Two different doses of cabazitaxel failed to show superiority with regard to overall survival over docetaxel as first-line treatment for patients with metastatic castration-resistant prostate cancer.

In this interview we discuss the ASCO provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer.

Taller men are at increased risk for high-grade prostate cancer and prostate cancer death, according to a large registry study. Greater adiposity is also associated with higher-grade tumors and mortality.

Long-term follow-up found no significant differences in all-cause or disease-related mortality in men with early prostate cancer randomized to either radical prostatectomy or to observation. Surgery led to more adverse events, but less treatment for disease progression.


Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.